The Online Investor
Daily M&A
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Tue., Sep. 30, 7:55 PM

Slide #3. Akorn Xopenex

Acquirer: Akorn (NASDAQ:AKRX)
Acquiree: Xopenex
Details: Akorn, Inc. (Nasdaq:AKRX), a niche pharmaceutical company, today announced that it has signed a definitive agreement ("Agreement") to acquire certain rights to short-acting bronchodilator Xopenex (levalbuterol HCI) Inhalation Solution (IS) from Sunovion Pharmaceuticals Inc. for $45 million, paid in cash at closing, net of certain liabilities. According to IMS Health, the U.S. market for both the generic and branded versions of Xopenex IS was approximately $280 million for the twelve-month period ending August 2014.

Akorn manufactures and markets a line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as hospital drugs and injectable pharmaceuticals. In addition, Co. manufactures and markets over-the-counter ophthalmic products for the treatment of dry eye under the TheraTears® brand name, as well as private label over-the-counter ophthalmic products. Co. provides diagnostic and therapeutic pharmaceutical products in various areas, including ophthalmology, antidotes, anti-infectives, vaccines, and controlled substances for pain management and anesthesia. Co.'s customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, and retail pharmacy chains.

Open the AKRX Page at The Online Investor »

Company Name:  Akorn Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding AKRX:  43
Total Market Value Held by ETFs:  $298.03M
Total Market Capitalization:  $3.72B
% of Market Cap. Held by ETFs:  8.02%

Open the AKRX Page at The Online Investor (in a new window) »

September 30, 2014    7:55 PM Eastern
Quotes delayed 20 minutes

Strong Buy (3.57 out of 4)
76th percentile
(ranked higher than approx. 76% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Mergers & Acquisitions | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.